InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
Mesutoclax is an important global asset of InnoCare in the field of hematology. This approval marks the Company will initiate the clinical trial for the fourth indication of our BCL2 inhibitor.
Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells.
Myelodysplastic syndrome (MDS) is a group of heterogeneous clonal myeloid diseases characterized by the abnormal proliferation of hematopoietic stem cells, recurrent genetic abnormalities, myelodysplasia, ineffective hematopoiesis, peripheral-blood cytopenia, and a high risk of progression to acute myeloid leukemia (AML). The annual incidence of myelodysplastic syndromes is about 4 cases/100,000 people/year (reaching 40–50/100,000 in patients aged ≥ 70 years).
Mesutoclax has been granted Breakthrough Therapy Designation (BTD) by the CDE for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This marks the first BCL2 inhibitor to receive BTD recognition in China. The Company is accelerating patient enrollment of a Phase III registrational trial of mesutoclax in combination with orelabrutinib as a first line therapy for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as a clinical trial of mesutoclax for the treatment of AML.
Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, 'Mesutoclax is an important global asset of our company in the field of hematology. We are delighted to receive approval to initiate the clinical trial for the fourth indication of our BCL2 inhibitor. We will accelerate the clinical development of mesutoclax across multiple indications in China and globally to bring benefits to patients as early as possible.'
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a few seconds ago
- Business Wire
Angel Oak Financial Strategies Income Term Trust Declares August 2025 Distribution
ATLANTA--(BUSINESS WIRE)--Angel Oak Financial Strategies Income Term Trust (the 'Fund'), a closed-end fund traded on the New York Stock Exchange under the symbol FINS, today declared a distribution of $0.115 per share for the month of August 2025, equating to an approximate 10% distribution on NAV. FINS intends to maintain its level distribution policy at the new higher distribution rate. The record date for the distribution is August 15, 2025, and the payable date is August 29, 2025. The Fund will trade ex-distribution on August 15, 2025. FINS increased the monthly distribution from $0.109 to $0.115 given the benefit to the Fund from higher coupon investments as Angel Oak Capital Advisors fully optimizes the portfolio into a robust primary issuance market following the recent Rights Offering. Angel Oak Capital Advisors' investment team rapidly deployed proceeds from the Rights Offering into money center and regional bank debt to eliminate cash drag. With the acceleration in the community bank debt issuance calendar, the team has re-deployed approximately half of the proceeds into higher-coupon community bank bonds (average coupon 7.68%, range: 7.00%-9.00%). Coupons on the new bonds are over 100 basis points higher than the Fund's average coupon of 6.51%, as of June 30, 2025. The near-term issuance pipeline remains robust. In addition to the immediate benefit from accretively deploying the new capital, the team believes several factors offer additional upside to NAV in the current environment: Positive tailwinds from strong banking sector fundamentals: Recent second quarter bank earnings highlighted strong credit, improving net interest margins and stronger loan growth. Legacy portfolio benefits from approaching call dates: Over $100 million of fixed rate bank debt in the portfolio will transition from fixed to floating rate over the next 24 months as the bonds enter their call period, resulting in higher coupons (based on current SOFR) and/or the bonds getting called and refinanced by the issuer. Increased M&A activity: Traditionally an alpha generator to the strategy, M&A activity has been accelerating in 2025 under a more favorable regulatory environment. Although the Fund seeks to pay a distribution at a rate that is representative of net investment income actually earned, a portion of each distribution may be treated as paid from sources other than net investment income, including, to the extent permitted by law, short-term capital gain, long-term capital gain, or return of capital. As required by Section 19(a) of the Investment Company Act of 1940, a notice will be distributed to shareholders in the event that a portion of a monthly distribution is derived from sources other than undistributed net investment income. The final determination of the source and tax characteristics of these distributions will depend upon the Fund's investment experience during its fiscal year and will be made after the Fund's year end. The Fund will send to investors a Form 1099-DIV for the calendar year that will define how to report these distributions for federal income tax purposes. ABOUT FINS Led by Angel Oak Capital Advisors' experienced financial services team, FINS invests predominantly in U.S. financial sector debt as well as selective opportunities across financial sector preferred and common equity. Under normal circumstances, at least 50% of FINS' portfolio is publicly rated investment grade or, if unrated, judged to be of investment grade quality by Angel Oak Capital Advisors. ABOUT ANGEL OAK CAPITAL ADVISORS, LLC Angel Oak Capital Advisors is an investment management firm focused on providing compelling fixed-income investment solutions to its clients. Backed by a value-driven approach, Angel Oak Capital Advisors seeks to deliver attractive, risk-adjusted returns through a combination of stable current income and price appreciation. Its experienced investment team seeks the best opportunities in fixed income, with a specialization in mortgage-backed securities and other areas of structured credit. Information regarding the Fund and Angel Oak Capital Advisors can be found at Past performance is neither indicative nor a guarantee of future results. Investors should consider the investment objective and policies, risk considerations, charges and ongoing expenses of an investment carefully before investing. For more information please contact your investment representative or Destra Capital Advisors LLC at 877.855.3434. © 2025 Angel Oak Capital Advisors, which is the investment adviser to the Angel Oak Financial Strategies Income Term Trust.
Business Wire
a few seconds ago
- Business Wire
Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for July 2025, Includes Reg.-NMS Execution Statistics
GREENWICH, Conn.--(BUSINESS WIRE)--Interactive Brokers Group, Inc. (Nasdaq: IBKR) an automated global electronic broker, today reported its Electronic Brokerage monthly performance metrics for July. Brokerage highlights for the month included: 3.498 million Daily Average Revenue Trades (DARTs) 1, 27% higher than prior year and 1% higher than prior month. Ending client equity of $685.8 billion, 35% higher than prior year and 3% higher than prior month. Ending client margin loan balances of $67.6 billion, 20% higher than prior year and 4% higher than prior month. Ending client credit balances of $144.3 billion, including $6.0 billion in insured bank deposit sweeps 2, 32% higher than prior year and about even with prior month. 3.958 million client accounts, 32% higher than prior year and 2% higher than prior month. 194 annualized average cleared DARTs 1 per client account. Average commission per cleared Commissionable Order 3 of $2.64 including exchange, clearing and regulatory fees. Key products: Futures include options on futures. We estimate exchange, clearing and regulatory fees to be 57% of the futures commissions. Other financial information for Interactive Brokers Group: GLOBAL 4: The value of the GLOBAL, reported in U.S. dollars, decreased by 0.73% in July and increased by 1.630% for the year to date. In the interest of transparency, we quantify our IBKR PRO clients' all-in cost of trade execution below. For the full multimedia release with graph see link: Average U.S. Reg-NMS stock trade was $19,605 in July (dividing 2c by 1a in table below). In June, IBKR PRO clients' total cost of executing and clearing U.S. Reg.-NMS stocks through IB was about 1.8 basis points of trade money 5, as, measured against a daily VWAP 6 benchmark (3.5 basis points net cost for the rolling twelve months). IBKR PRO Clients' Reg.-NMS Stock Trading Expense Detail All amounts are in millions, except % Previous Aug '24 Sep '24 Oct '24 Nov '24 Dec '24 Jan '25 Feb '25 Mar '25 Apr '25 May '25 June '25 July '25 12 Months #1a - Number of orders Buys 9.84 8.38 10.93 11.40 13.32 12.74 12.40 12.19 13.79 12.15 12.36 13.94 143.44 Sells 7.53 6.54 8.33 8.62 9.66 8.97 9.08 8.71 10.16 9.49 9.57 10.51 107.17 Total 17.37 14.92 19.26 20.02 22.98 21.71 21.48 20.90 23.95 21.65 21.94 24.45 250.61 #1b - Number of shares purchased or sold Shares bought 4,154 3,614 4,645 4,744 5,517 5,223 4,946 5,047 6,008 5,659 5,422 6,915 61,892 Shares sold 3,960 3,436 4,390 4,497 5,232 4,868 4,738 4,804 5,850 5,212 5,100 6,444 58,530 Total 8,114 7,050 9,035 9,241 10,749 10,090 9,683 9,851 11,858 10,871 10,522 13,358 120,422 #2 - Trade money including price, commissions and fees 2a Buy money $182,908 $155,758 $190,627 $204,300 $214,806 $208,418 $200,026 $216,767 $254,062 $222,977 $222,050 $242,089 $2,514,788 2b Sell money $186,274 $154,825 $188,444 $201,932 $215,520 $203,359 $204,689 $218,670 $259,783 $219,486 $219,444 $237,255 $2,509,681 2c Total $369,182 $310,583 $379,071 $406,232 $430,326 $411,778 $404,715 $435,437 $513,845 $442,463 $441,494 $479,345 $5,024,470 #3 - Trade value at Daily VWAP 3a Buy value $182,849 $155,692 $190,537 $204,249 $214,660 $208,258 $199,957 $216,676 $254,052 $223,005 $222,033 $241,994 $2,513,962 3b Sell value $186,440 $154,890 $188,493 $201,995 $215,621 $203,305 $204,744 $218,725 $259,985 $219,608 $219,540 $237,248 $2,510,596 3c Total $369,289 $310,582 $379,030 $406,243 $430,281 $411,563 $404,702 $435,401 $514,038 $442,613 $441,573 $479,242 $5,024,557 #4 - Total trade expense, including commissions and fees, relative to Daily VWAP 4a Buys (2a-3a) $58.6 $66.6 $90.7 $51.4 $145.7 $160.6 $68.5 $90.6 $9.6 ($28.0) $17.0 $95.3 $826.6 4b Sells (3b-2b) $166.0 $65.7 $49.6 $62.3 $100.9 ($54.3) $55.2 $55.2 $202.8 $122.0 $96.5 ($7.6) $914.4 4c Total trade expense $224.6 $132.3 $140.3 $113.8 $246.6 $106.4 $123.7 $145.8 $212.4 $94.0 $113.5 $87.7 $1,740.9 Trade expense as percentage of trade money 4c/2c 0.061% 0.043% 0.037% 0.028% 0.057% 0.026% 0.031% 0.033% 0.041% 0.021% 0.026% 0.018% 0.035% #5 - Trade expense categories 5a Total commissions & fees $38.1 $33.2 $41.9 $43.5 $47.4 $46.2 $45.5 $45.7 $52.7 $44.5 $41.5 $51.4 $531.6 5b Execution cost (4c-5a) $186.5 $99.1 $98.4 $70.3 $199.2 $60.2 $78.2 $100.0 $159.7 $49.5 $72.0 $36.3 $1,209.4 #6 - Trade expense categories as percentage of trade money Total commissions & fees (5a/2c) 0.010% 0.011% 0.011% 0.011% 0.011% 0.011% 0.011% 0.010% 0.010% 0.010% 0.010% 0.010% 0.011% Execution cost (5b/2c) 0.051% 0.032% 0.026% 0.017% 0.046% 0.015% 0.020% 0.023% 0.031% 0.011% 0.016% 0.008% 0.024% Net Expense to IB Clients 0.061% 0.043% 0.037% 0.028% 0.057% 0.026% 0.031% 0.033% 0.041% 0.021% 0.026% 0.018% 0.035% Expand The above illustrates that the rolling twelve months' average all-in cost of an IBKR PRO client U.S. Reg.-NMS stock trade was 3.5 basis points. ________________ Note 1: Daily Average Revenue Trades (DARTs) – customer orders divided by the number of trading days in the period. Note 2: FDIC insured client bank deposit sweep program balances with participating banks. These deposits are not reported in the Company's statement of financial condition. Note 3: Commissionable Order – a customer order that generates commissions. Note 4: In connection with our currency diversification strategy, we have determined to base our net worth in GLOBALs, a basket of 10 major currencies in which we hold our equity. The total effect of the currency diversification strategy is reported in Comprehensive Income and the components are reported in (1) Other Income and (2) Other Comprehensive Income ('OCI') on the balance sheet. The effect of the GLOBAL on our comprehensive income can be estimated by multiplying the total equity for the period by the change in the U.S. dollar value of the GLOBAL during the same period. Note 5: Trade money is the total amount of money clients spent or received, including all commissions and fees. Note 6: Consistent with the clients' trading activity, the computed VWAP benchmark includes extended trading hours. _________________ More information, including historical results for each of the above metrics, can be found on the investor relations page of the Company's corporate web site, About Interactive Brokers Group, Inc.: Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities, foreign exchange, and forecast contracts around the clock on over 160 markets in numerous countries and currencies from a single unified platform to clients worldwide. We serve individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation have enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Interactive Brokers has consistently earned recognition as a top broker, garnering multiple awards and accolades from respected industry sources such as Barron's, Investopedia, and many others. Cautionary Note Regarding Forward-Looking Statements: The foregoing information contains certain forward-looking statements that reflect the company's current views with respect to certain current and future events and financial performance. These forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and factors relating to the company's operations and business environment which may cause the company's actual results to be materially different from any future results, expressed or implied, in these forward-looking statements. Any forward-looking statements in this release are based upon information available to the company on the date of this release. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any statements expressed or implied therein will not be realized. Additional information on risk factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.
Business Wire
31 minutes ago
- Business Wire
BioConsortia Closes Financing to Accelerate Launch of Next-Generation Nitrogen-Fixing Biofertilizer and Fuel Global Expansion
BUSINESS WIRE)--BioConsortia, Inc., a leader in microbial innovation for sustainable agriculture, announced today it has secured $15 million in funding from its long-standing internal investors, led by Otter Capital and affiliated funds. 'This investment, one in a series of recurring financings from our internal investors, reflects their deep confidence in BioConsortia's science, strategy, and commercial momentum,' said Marcus Meadows-Smith, BioConsortia's CEO. 'Their investments total $95 million and bring BioConsortia to this exciting moment in the company's history.' The new funding will accelerate the global launch of Always-N™, BioConsortia's groundbreaking nitrogen-fixing seed treatment for industrial corn and support continued expansion of its discovery and development engine at the company's Davis, California headquarters. Always-N enables farmers to maintain crop yields while reducing reliance on synthetic nitrogen fertilizers—significantly lowering greenhouse gas emissions and improving soil health. Applied as a seed treatment, Always-N delivers consistent field performance and is the only nitrogen-fixing biofertilizer combining advanced gene editing and extended viability exceeding two years. "Synthetic nitrogen fertilizers are essential to modern agriculture, but their overuse comes at a steep environmental cost,' said Meadows-Smith. 'With Always-N, we offer a powerful, sustainable alternative—backed by cutting-edge science and built for real-world performance.' Roughly half of applied synthetic nitrogen is never absorbed by crops. Instead, it runs off into waterways or is broken down in soil, releasing nitrous oxide—a greenhouse gas 300 times more potent than CO₂. As regulatory and market pressure builds for climate-smart farming, demand for sustainable alternatives like Always-N is growing rapidly. Following its successful commercial debut in New Zealand in 2024, Always-N is now preparing for broader market entry, supported by key global partners including The Mosaic Company in row crops in the Americas. The new funding enables BioConsortia to scale manufacturing, build inventory, and expand market access in anticipation of the upcoming growing season. Always-N is powered by BioConsortia's discovery and development platform - an integrated engine using proprietary tools for microbial discovery, selection, and optimization. It begins with Advanced Microbial Selection™ (AMS) to identify high-performing plant-associated microbes, then uses GenExpress™ and GenePro™ tools to enhance traits such as nitrogen fixation, disease and pest control, and shelf-life. In addition to Always-N™, BioConsortia is advancing a robust pipeline of next-generation biostimulants, fungicides, nematicides, and insecticides—engineered for extended shelf life, ease of use, and superior field efficacy. Since its founding in 2014, BioConsortia has validated its platform across diverse crops, geographies, and soil types. Field trials have consistently demonstrated the efficacy of its microbial biofertilizers, fungicides, nematicides, and insecticides—delivering growers new tools for sustainable, high-yield farming. About BioConsortia At BioConsortia, we are pioneering the next generation of agricultural biologicals through cutting-edge microbial gene editing. Our breakthroughs in editing only the most stable microbes unlock unprecedented performance in nitrogen fixation, biocontrol, and biostimulants—delivering solutions that are more effective, more consistent, and easier to use than anything on the market today. By precisely enhancing natural microbial traits, we're creating products that outperform both traditional chemicals and first-generation biologicals—with longer shelf life, extended life on seed, robust field efficacy, and compatibility with existing farm systems. Our AMS platform supports rapid discovery and development of superior wild type microbial products, and our gene-edited innovations redefine what's possible in sustainable agriculture. Since its founding in 2014, BioConsortia has built a reputation for delivering science-driven, field-proven solutions across a wide range of crops, geographies, and growing conditions. Today, the company stands at the forefront of the agricultural biologicals revolution—offering farmers the tools to grow more with less, and do so sustainably.
